CRO KCR expands further into Western Europe

By Zahcary Brennan

- Last updated on GMT

KCR, CRO, Europe, Germany, UK, clinical development
KCR, CRO, Europe, Germany, UK, clinical development
European CRO KCR has registered two new entities in the UK and Germany, which adds to its presence in 18 countries in Europe as well as the US. 

The registration of new entities in the UK and Germany is part of the company’s strategy to bring the business closer to Western European customers and further deepen client relationships.

KCR has a history of supporting projects in these countries​,” KCR CEO Mike Jagielski told “From that point of view, the decision to expand in these regions has been a logical step.

In addition, we also have long standing agreements with a network of medical and operations experts in these countries. UK, Germany and France remain key research markets and it is important for our European Strategy to directly provide the support​.”

Eyes East

KCR offers three types of professional contract research services: clinical development services, functional service provision and post-marketing clinical services for a spectrum of therapeutic areas.

We are able to directly cover large part of Europe without the consideration of subcontracting​,” Jagielski told us. “In addition, we see the boundaries between CEE [Central and Eastern Europe] and Western Europe are being more and more reduced​.

Companies will decide to go to Europe and less and less it will be a decision about CEE or Western Europe. KCR has to be prepared for that​.”

He added that the company already has partnerships with locally based or represented companies in the UK and Germany. “It will also equip KCR with local law benefits and make our business cooperation easier. The next country we aim for is France​,” Jagielski added.

Since its early days of forging a path in CEE, KCR continues to develop and expand east and across Western Europe. Having a local team in each of the offices gives the company a unique insight into local regulations, the company said, noting extensive relationships with key opinion leaders and principal investigators.

KCR will support Phase II through Phase IV studies in the UK and Germany, Jagielski said.

Related news

Show more

Related products


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers